CHICAGO, Aug. 17 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company will participate in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (www.icaac.org ). The International conference will be held in Boston, Massachusetts, September 12–15, 2010.
As an exhibitor at this year's conference, Advanced Life Sciences will update and interact with more than 10,000 physicians, researchers and other healthcare professionals from around the globe who will gather at the 50th ICAAC to focus on solutions to the problem of infectious disease. Data on the Company's lead product, Restanza™ (cethromycin), its novel once-daily oral antibiotic, will be presented showing the drug's efficacy against 30 strains of Burkholderia pseudomallei, a serious, life-threatening bacterial pathogen that is also a potential agent of biological warfare or bioterrorism, and is listed on the Centers for Disease Control list as a Category B bioterrorism agent. Restanza showed significant in vitro activity against clinical and environmental strains of B. pseudomallei as measured by minimal inhibitory concentration (MIC), the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after 24 hours of incubation. Restanza demonstrate